Acusphere reaches deal with FDA
Article Thumbnail ImageJune 8, 2011 -- Ultrasound contrast developer Acusphere has signed a special protocol assessment agreement with the U.S. Food and Drug Administration (FDA) for the design of a new phase III study of its Imagify agent.
Member Sign In:
  MemberID or E-mail Address:
  Password:
(?)

New AuntMinnie.com Members

Becoming a Member is FREE!

  • Real-time radiology-specific news
  • Case of the Day and Teaching Files
  • Focused topics digital communities
  • Lively, discussion groups
  • Medical imaging bookstore
  • SalaryScan
  • Job Boards
  • Online CME
  • Bookstore, market reports, more …
  • Conference Calendar
  • User-controlled eNewsletters
  • … registration is FREE and easy!
  • The study will compare stress ultrasound with Imagify to unenhanced stress ultrasound for detecting coronary artery disease, according to Acusphere. The FDA had requested a placebo-controlled phase III trial for Imagify to supplement earlier trials that compared Imagify's efficacy with nuclear stress testing.

    Based upon an enrollment of 900 patients, the company expects the new trial will cost approximately $15 million and require approximately two years to complete.


    || About || Advertising || AuntMinnieCME.com || Bookstore || Breast MRI || Career Center || Case of the Day || Communities || Conferences || Contact Us || ECR News 2014 || Education || Equipment Classifieds || Europe || Facebook || Forums || Home || Links || Marketplace || Middle East || Mobile || Molecular Breast Imaging || New Installations || News in Brief || People in the News || Privacy Policy || RSNA News 2013 || Reference || Salary Survey Results || Trends in Radiology || Twitter || Vendor Connect || Webinars || XML/RSS ||

    Copyright © 2014 AuntMinnie.com. All Rights Reserved.